The role of long non-coding RNAs in developing paclitaxel-resistant triple negative breast cancer: a systematic review.

INTRODUCTION

Recent evidence supports the idea that long non-coding RNAs (lncRNAs) are significantly involved in chemoresistance of breast cancer. This study aimed to systematically review the emerging role of lncRNAs in paclitaxel (PTX) resistance in triple-negative breast cancer (TNBC). Furthermore, the review summarized potential targets and the underlying mechanisms of lncRNAs to induce or reverse the resistance of TNBC cells to PTX.

METHODS

The PubMed, Scopus, and Web of Science databases were searched for studies on lncRNAs involved in the resistance of TNBC cells to PTX using specific terms related to TNBC, lncRNAs, resistance, and paclitaxel. Relevant English articles published until November 2023, were systematically reviewed based on inclusion and exclusion criteria. Quality of the included studies was assessed using the Würzburg Methodological Quality Score (W-MeQS) by two independent authors.

RESULTS

A total of 95 publications were initially identified, and after applying the inclusion and exclusion criteria, 19 articles were included in this systematic review. These studies investigated the role of critical lncRNAs in PTX-resistant TNBC. Regulating the cell cycle and apoptosis, epithelial-to-mesenchymal transition, autophagy, and angiogenesis are the main mechanisms through which lncRNAs affect the resistance to PTX in TNBC.

CONCLUSION

This systematic review highlights the significant role of lncRNAs in promoting or inhibiting the resistance of TNBC cells to PTX. The lncRNAs with upregulated or downregulated expression in PTX-resistant TNBC may provide promising therapeutic targets to enhance the efficacy of chemotherapy.